-
公开(公告)号：US20120202755A1
公开(公告)日：2012-08-09
申请号：US13501208
申请日：2010-09-30
申请人： Tao Wang , Yi Zhang , Erwei Liu , Lifeng Han , Dandan Ge , Xiumei Gao
发明人： Tao Wang , Yi Zhang , Erwei Liu , Lifeng Han , Dandan Ge , Xiumei Gao
IPC分类号： A61K31/7028 , A61P3/10 , C07H7/04
摘要： Foliamngiferosides having the general formula (I) are disclosed, wherein R is H or —OCH. The preparation method of the compounds, pharmaceutical compositions comprising the compounds as the active ingredients, the use of the compounds and the pharmaceutical compositions for inhibiting the activity of α-glucosidase are also disclosed.The foliamangiferosides can be used in preparing drugs for treating diabetes.
摘要翻译： 公开了具有通式（I）的叶绿素苷，其中R是H或-OCH。 还公开了该化合物的制备方法，包含该化合物作为活性成分的药物组合物，该化合物和药物组合物用于抑制α-葡糖苷酶活性的用途。 叶黄素可用于制备治疗糖尿病的药物。
-
公开(公告)号：US08829167B2
公开(公告)日：2014-09-09
申请号：US13501208
申请日：2010-09-30
申请人： Tao Wang , Yi Zhang , Erwei Liu , Lifeng Han , Dandan Ge , Xiumei Gao
发明人： Tao Wang , Yi Zhang , Erwei Liu , Lifeng Han , Dandan Ge , Xiumei Gao
摘要： Foliamngiferosides having the general formula (I) are disclosed, wherein R is H or —OCH. The preparation method of the compounds, pharmaceutical compositions comprising the compounds as the active ingredients, the use of the compounds and the pharmaceutical compositions for inhibiting the activity of α-glucosidase are also disclosed. The foliamangiferosides can be used in preparing drugs for treating diabetes.
摘要翻译： 公开了具有通式（I）的叶绿素苷，其中R是H或-OCH。 还公开了该化合物的制备方法，包含该化合物作为活性成分的药物组合物，该化合物和药物组合物用于抑制α-葡糖苷酶活性的用途。 叶黄素可用于制备治疗糖尿病的药物。
-
3.发明申请公开(公告)号：US20070076936A1
公开(公告)日：2007-04-05
申请号：US11240763
申请日：2005-09-30
CPC分类号： G16B30/00 , G06K9/6206
摘要： Large scale sequences and other types of patterns may be matched or aligned quickly using a linear space technique. In one embodiment, the invention includes, calculating a similarity matrix of a first sequence against a second sequence, determining a lowest cost path through the matrix, where cost is a function of sequence alignment, dividing the similarity matrix into a plurality of blocks, determining local start points on the lowest cost path, the local start points each corresponding to a block through which the lowest cost path passes, dividing sequence alignment computation for the lowest cost path into a plurality of independent problems based on the local start points, solving each independent problem independently, and concatenating the solutions to generate an alignment path of the first sequence against the second sequence.
摘要翻译： 使用线性空间技术可以快速匹配或对齐大规模序列和其他类型的图案。 在一个实施例中，本发明包括：计算第一序列与第二序列的相似度矩阵，确定通过矩阵的最低成本路径，其中成本是序列比对的函数，将相似性矩阵划分为多个块，确定 最低成本路径上的本地起始点，每个对应于最低成本路径通过的块的本地起始点，基于本地起始点将最低成本路径的序列比对计算分解为多个独立问题，解决每个 独立的问题，并且连接解决方案以产生第一序列与第二序列的对准路径。
-
公开(公告)号：US20050053682A1
公开(公告)日：2005-03-10
申请号：US10658194
申请日：2003-09-10
申请人： Yi Zhang , Yi Zhang , Qingjiang Wu
发明人： Yi Zhang , Yi Zhang , Qingjiang Wu
IPC分类号： A61K31/365 , A61K31/366 , A61K31/37 , A61K31/4741 , A61K36/75 , A61K35/78
CPC分类号： A61K36/75
摘要： Methods and uses pertaining to the oral treatment of anorectal conditions in a man or woman in need of such treatment are described, which comprises treatment with an orally effective amount of an extract of Cortex Dictamni in unit dosage form in association with one or more carriers or excipients.
摘要翻译： 描述了与需要这种治疗的男性或女性口腔治疗肛门直肠病症有关的方法和用途，其包括以口服有效量的单位剂量形式的皮质硬脑膜炎提取物与一种或多种载体或 赋形剂。
-
公开(公告)号：US20230138190A1
公开(公告)日：2023-05-04
申请号：US18091673
申请日：2022-12-30
申请人： Yi Zhang , Maruti Gupta Hyde , Ziyi LI , Vaibhav Singh , Christian Maciocco , Jaemin Han
发明人： Yi Zhang , Maruti Gupta Hyde , Ziyi LI , Vaibhav Singh , Christian Maciocco , Jaemin Han
摘要： An apparatus and system of providing energy saving in a network are described. A target node receives, from a source node, a handover request to handover a UE due to at least one of entry of the source node into a power saving state or mobility optimization. In response, the target node transmits a relative energy efficiency value of Bits per Joule and periodic feedback related to a status of the UE for training an AI/ML energy saving model and stops the feedback in response to a stop parameter being met. The stop parameter is a first of: a predicted period of the source node to stay in the power saving state or time for a UE to connect to the target node, a percentage of UEs handed over that enter an idle or inactive state, and a percentage of UEs handed over that are further handed to another node.
-
公开(公告)号：US20230015807A1
公开(公告)日：2023-01-19
申请号：US17859542
申请日：2022-07-07
申请人： Yi Zhang
发明人： Yi Zhang
IPC分类号： A61N7/02
摘要： The present disclosure relates to transcranial ultrasound systems, devices, and methods which are used for treatment rather than for imaging or medical diagnosis. In accordance with one aspect, a system for applying ultrasound energy includes at least three ultrasound applicators configured to be secured against a head of a person and configured to apply ultrasound energy to the head of the person when activated, and a controller configured to control activation and deactivation of the at least three ultrasound applicators based on a predetermined treatment sequence.
-
-
公开(公告)号：US11124527B2
公开(公告)日：2021-09-21
申请号：US15579830
申请日：2016-06-03
申请人： Syros Pharmaceuticals, Inc. , Christopher Roberts , Yi Zhang , Francis Beaumier , Luce Lépissier
发明人： Jason J. Marineau , Peter B. Rahl , Kevin Sprott , Stephane Ciblat , Boubacar Sow , Robin Larouche-Gauthier , Lauren Berstler , Christopher Roberts , Yi Zhang , Francis Beaumier , Luce Lépissier
IPC分类号： C07D513/04 , A61P35/00 , C07D495/04
摘要： The present invention provides novel compounds of Formulas (I) and (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases, e.g., cancers (e.g., breast cancer, prostate cancer, lymphoma, lung cancer, pancreatic cancer, ovarian cancer, neuroblastoma, or colorectal cancer), benign neoplasms, angio genesis, inflammatory diseases, fibrosis (e.g., polycystic kidney disease), autoinflammatory diseases, and autoimmune diseases in a subject.
-
公开(公告)号：US10893824B2
公开(公告)日：2021-01-19
申请号：US13306343
申请日：2011-11-29
摘要： A system and method for automatically analyzing heart failure in a patient, including collecting physiological data from a patient using at least a first sensor and a second sensor to collect two or more sensor measurements, and calculating a first composite value based on at least a first sensor measurement wherein the first composite value is an indication of a likelihood that the patient's heart failure status has changed. If the first composite value is outside of a first specified range, then a second composite value is calculated based on at least a second sensor measurement, wherein the second composite value is an indication of a likelihood that the patient's heart failure status has changed. If the second composite value is outside of a second specified range, then an alert of change in heart failure status is generated.
-
公开(公告)号：US10469178B2
公开(公告)日：2019-11-05
申请号：US14239834
申请日：2011-08-22
摘要： A method including determining if there is in device co-existence interference during operation of the device; and causing information about in device co-existence interference and information about measurements performed by the device to be transmitted to a base station.
-
-
-
-
-
-
-
-
-
搜索结果
546 条记录 (耗时 0.033 秒)
